SPINE BIOLOGICS MARKET ANALYSIS
Global Spine Biologics Market – Regional Insights
North America is expected to dominate the global spine biologics market, owing to the continuous registrations and approvals of spine biologics by the U.S. Food and Drug Administration (FDA). For instance, on February 25, 2020, EmCyte, one of the global leaders in platelet rich plasma and progenitor stem cell biologics, received FDA 510 (k) clearance for its PurePRP SupraPhysiologic Concentrating System for platelet rich plasma.
Furthermore, Europe region is expected to witness a significant growth in the forecast period, due to emerging cases of spinal cord injury (SCI) and spine muscular atrophy, thereby increasing the need for spine biologics-based therapies. For instance, according to National Health Service (NHS), UK, in England in 2017-18, there were approximately 1200 new spinal cord injury cases that required admission of the patients into a spinal cord injury center. In addition, in 2019, 600 children and 1,200 adults were reported to have spine muscular atrophy in England and Wales. These factors are expected to support global spine biologics market growth over the forecast period.
Spine Biologics Market Report Snapshots
Need a Custom Report?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize NowWant to Buy a Report but have a Limited Budget?
We help clients to procure the report or sections of the report at their budgeted price. Kindly click on the below to avail
Request Discount
Credibility and Certifications
9001:2015
27001:2022
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients